Sierra Oncology, Inc. (NASDAQ:SRRA) Expected to Post Earnings of -$0.91 Per Share

Equities research analysts expect Sierra Oncology, Inc. (NASDAQ:SRRAGet Rating) to report ($0.91) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the highest EPS estimate coming in at ($0.85) and the lowest estimate coming in at ($0.97). Sierra Oncology reported earnings per share of ($1.71) during the same quarter last year, which would indicate a positive year over year growth rate of 46.8%. The company is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Sierra Oncology will report full year earnings of ($4.88) per share for the current year, with EPS estimates ranging from ($5.91) to ($3.90). For the next financial year, analysts expect that the business will post earnings of ($3.60) per share, with EPS estimates ranging from ($4.42) to ($3.10). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Sierra Oncology.

Sierra Oncology (NASDAQ:SRRAGet Rating) last posted its quarterly earnings results on Thursday, March 10th. The biotechnology company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.07).

A number of analysts have issued reports on SRRA shares. Zacks Investment Research upgraded shares of Sierra Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, January 22nd. Lifesci Capital cut shares of Sierra Oncology from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 13th. Jefferies Financial Group cut shares of Sierra Oncology from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $39.00 to $55.00 in a research note on Thursday, April 14th. HC Wainwright cut shares of Sierra Oncology from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $51.00 to $55.00 in a research note on Wednesday, April 13th. Finally, Oppenheimer cut shares of Sierra Oncology from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $45.00 to $55.00 in a research note on Thursday, April 14th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $51.00.

NASDAQ SRRA opened at $54.51 on Monday. The stock has a market capitalization of $1.29 billion, a PE ratio of -7.62 and a beta of 0.57. The company has a 50 day moving average price of $38.94 and a two-hundred day moving average price of $28.96. Sierra Oncology has a 12-month low of $14.91 and a 12-month high of $54.97.

In other Sierra Oncology news, major shareholder Longitude Capital Partners Iii purchased 175,000 shares of the stock in a transaction on Wednesday, February 2nd. The shares were purchased at an average price of $27.00 per share, with a total value of $4,725,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Mary Christina Thomson sold 2,000 shares of the business’s stock in a transaction on Friday, February 4th. The shares were sold at an average price of $29.78, for a total transaction of $59,560.00. The disclosure for this sale can be found here. Insiders sold a total of 17,553 shares of company stock worth $584,717 in the last three months. Insiders own 67.68% of the company’s stock.

Several large investors have recently modified their holdings of the company. Elmwood Wealth Management Inc. acquired a new position in Sierra Oncology during the 4th quarter worth about $25,000. JPMorgan Chase & Co. lifted its position in Sierra Oncology by 1,200.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,300 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,200 shares in the last quarter. Dorsey Wright & Associates acquired a new position in Sierra Oncology during the 1st quarter worth about $48,000. Acadian Asset Management LLC acquired a new position in Sierra Oncology during the 4th quarter worth about $79,000. Finally, Citigroup Inc. acquired a new position in Sierra Oncology during the 4th quarter worth about $160,000.

Sierra Oncology Company Profile (Get Rating)

Sierra Oncology, Inc, a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor.

Recommended Stories

Get a free copy of the Zacks research report on Sierra Oncology (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.